New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy

INTRODUCTION: The most recently approved antiretroviral, the integrase inhibitor dolutegravir (DTG), is described to be a very potent drug with a unique resistance profile, but a certain degree of cross-resistance to RAL or EVG induced drug resistance, which is mediated mainly by integrase mutations...

Descripción completa

Detalles Bibliográficos
Autores principales: Carganico, Andreas, Dupke, Stefan, Ehret, Robert, Berg, Thomas, Baumgarten, Axel, Obermeier, Martin, Walter, Hauke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Poster Sessions – Abstract P217
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225390/
https://www.ncbi.nlm.nih.gov/pubmed/25397494
http://dx.doi.org/10.7448/IAS.17.4.19749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225390/
https://www.ncbi.nlm.nih.gov/pubmed/25397494
http://dx.doi.org/10.7448/IAS.17.4.19749

Ejemplares similares